Mazdutide

Phase 3Peptide

Eli Lilly

Mazdutide is one of 195 small molecule programs targeting Gout. It is currently in Phase 3.

Indications

Total Trials

Active Trials

194

Competitors

Pipeline

Status by Indication[3][1]

Indication

GoutNot yet recruiting

Type 2 Diabetes Mellitus (T2DM)Not yet recruiting

Metabolic Dysfunction-Associated SteatohepatitisNot yet recruiting

Diabetes Mellitus, Type 2Not yet recruiting

ObesityNot yet recruiting

CirrhosisNot yet recruiting

Dementia, MildRecruiting

Fatty PancreasNot yet recruiting

Diabetic Kidney DiseaseNot yet recruiting

Obesity & OverweightNot yet recruiting

GoutPhase 3

Not yet recruiting

Type 2 Diabetes Mellitus (T2DM)Preclinical

Not yet recruiting

Metabolic Dysfunction-Associated SteatohepatitisPreclinical

Not yet recruiting

Diabetes Mellitus, Type 2Preclinical

Not yet recruiting

ObesityPhase 2

Not yet recruiting

CirrhosisPreclinical

Not yet recruiting

Dementia, MildPhase 3

Recruiting

Fatty PancreasPreclinical

Not yet recruiting

Diabetic Kidney DiseasePhase 3

Not yet recruiting

Obesity & OverweightPhase 3

Not yet recruiting

Showing 10 of 11 indications

Competition

Competitive Landscape

190 competitors in Obesity

#DrugCompanyPhaseTrials

Maridebart Cafraglutide

Amgen

Phase 3

7 2

Retatrutide

Eli Lilly

Phase 3

6 3

NNC0487-0111

Novo Nordisk

Phase 3

11 4

Mazdutide

Eli Lilly

Phase 3

2 5

HRS9531

FFujian Shengdi Pharmaceutical Co., Ltd.

Phase 3

1 6

Eloralintide

Eli Lilly

Phase 3

10 7

Ribupatide

KKailera

Phase 3

3 8

Elecoglipron

AstraZeneca

Phase 3

1 9

Survodutide

Boehringer Ingelheim

Phase 3

2 10

Avapro

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 3Not yet recruiting

Metformin

NCT07417306

ApprovedNot yet recruiting

Obesity & Overweight

NCT07657676

Q1 2028

PreclinicalNot yet recruiting

Type 2 Diabetes Mellitus (T2DM)

NCT07713992

ApprovedNot yet recruiting

Gout

NCT07824895

Q3 2028

PreclinicalNot yet recruiting

Metabolic Dysfunction-Associated Steatohepatitis

NCT07718126

Q4 2028

PreclinicalRecruiting

Obesity

NCT07517042

Clinical

Trials by Indication[1]

Obesity2 trials

Achieving Sustained Weight Control Via Exercise, Nutrition & Drugs (Mazdutide) (ASCEND- 1 Trial)

Recruiting·SShanghai Zhongshan Hospital·Preclinical·NCT07517042·420 enrolled

Mazdutide Plus Levonorgestrel-Releasing Intrauterine System for Fertility-Sparing Treatment in Overweight or Obese Patients With Atypical Endometrial Hyperplasia or Early Endometrioid Endometrial Cancer

Not yet recruiting·TTongji Hospital·Phase 2·NCT07781150·128 enrolled

Metformin1 trial

A Study of HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor

Not yet recruiting·HHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.·Phase 3·NCT07417306·912 enrolled

Efficacy1 trial

Efficacy of Mazdutide for Treating PCOS

Recruiting·SShanghai Zhongshan Hospital·Phase 1/2·NCT06519656·50 enrolled

Fatty Pancreas1 trial

Efficacy of Mazdutide on Fatty Pancreas in Overweight or Obese Adults: A Randomized Controlled Trial

Not yet recruiting·TTongji Hospital·Preclinical·NCT07803705·194 enrolled

Gout1 trial

A Single-Arm, Open-Label, Pre-Post Controlled Clinical Study to Evaluate the Effect of Mazdutide on Annualized Flare Rate in Adults With Obesity and Gout

Not yet recruiting·HHongwei Jiang·Approved·NCT07824895·30 enrolled

8 more indications

Not yet recruiting·CChina National Center for Cardiovascular Diseases·Approved·NCT07657676·116 enrolled

Diabetic Kidney Disease1 trial

QUAdruple Therapy With RASi, Empagliflozin, Finerenone, and Mazdutide in Type 2 Diabetes and Early Treatment of Nephropathy(QUARTET-DKD)

Not yet recruiting·HHuijie Zhang·Approved·NCT07775846·820 enrolled

Diabetes Mellitus, Type 21 trial

Mazdutide for Remission of Type 2 Diabetes: Multicentre, Double Blind, Randomised, Placebo Controlled Trial

Not yet recruiting·YYanbing Li·Preclinical·NCT07767552·249 enrolled

Metabolic Dysfunction-associated Steatohepatitis1 trial

Short-term Mazdutide Plus Lifestyle Intervention Versus Placebo for Pre-hepatectomy Prehabilitation in Living Liver Donors With MASLD: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial

Not yet recruiting·WWest China Hospital·Preclinical·NCT07718126·60 enrolled

Type 2 Diabetes Mellitus (T2DM)1 trial

Efficacy and Safety of Mazdutide in Patients With Type 2 Diabetes Mellitus and Moderate to Severe Nonalcoholic Fatty Liver Disease Previously Treated With Semaglutide: A Multicenter, Prospective, Randomized Controlled Trial (IIT)

Not yet recruiting·TTianjin Medical University·Preclinical·NCT07713992·72 enrolled

Alcohol Use Disorder1 trial

A Phase 2, Double-Blind, Proof of Concept Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT06817356·308 enrolled

Sources

References

[1]
ClinicalTrials.gov — 14 trial records for Mazdutide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Mazdutide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Mazdutide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eli Lilly company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Peptide[2]
Highest Phase: Phase 3[1]
Company: Eli Lilly

Mazdutide

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q1 2028

Q3 2028

Q4 2028

Trials by Indication[1]

Obesity2 trials

Metformin1 trial

Efficacy1 trial

Fatty Pancreas1 trial

Gout1 trial

Dementia, Mild1 trial

Cirrhosis1 trial

Obesity & Overweight1 trial

Diabetic Kidney Disease1 trial

Diabetes Mellitus, Type 21 trial

Metabolic Dysfunction-associated Steatohepatitis1 trial

Type 2 Diabetes Mellitus (T2DM)1 trial

Alcohol Use Disorder1 trial

References

Drug Info

Quick Facts

Related News